DSwiss, Inc. (DQWS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DSwiss, Inc. (DQWS) trades at $0.04 with AI Score 54/100 (Grade B). DSwiss, Inc. is a Malaysian biotech-nutraceutical company that develops and distributes health and beauty products across Asia. Market cap: $8.69M, Sector: Consumer defensive.
Last analyzed: Mar 17, 2026Analyst Coverage for DQWS: DQWS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DQWS against Consumer Defensive peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
DQWS: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
DSwiss, Inc. (DQWS) Consumer Business Overview
DSwiss, Inc. is a biotech-nutraceutical company based in Malaysia, focusing on health and beauty products across Asian markets. With a diverse product line from coffee to skincare, DSwiss aims to address consumer needs in digestive health, immunity, and overall well-being, operating in a competitive consumer defensive sector.
What Is the Investment Thesis for DQWS?
DSwiss, Inc. presents a speculative investment opportunity within the biotech-nutraceutical sector, characterized by a small market capitalization of $0.01 billion and negative profitability metrics, including a P/E ratio of -152.18 and a profit margin of -1.2%. The company's diverse product range and geographic reach across Asian markets offer potential growth avenues. However, the company's OTC listing and negative beta of -0.72 indicate higher risk and volatility. Key growth catalysts include expanding its product line and penetrating deeper into existing markets. The company's ability to achieve profitability and manage its operational costs will be crucial in determining its long-term success. Investors should carefully consider the risks associated with investing in a small-cap, OTC-listed company with negative profitability.
Based on FMP financials and quantitative analysis
DQWS Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -152.18 reflects current unprofitability, requiring investors to focus on future earnings potential.
- Gross margin of 16.5% suggests challenges in cost management and pricing strategy.
- Negative beta of -0.72 indicates an inverse correlation with the market, potentially offering diversification benefits but also reflecting business-specific risks.
- Presence in multiple Asian markets including Malaysia, Singapore, and China, provides geographic diversification and access to growing consumer markets.
Who Are DQWS's Competitors?
DQWS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BABB BAB, Inc. | $0.89 | +0.01% | $6.48M | 49 |
| FACYF Fancl Corporation | $17.45 | +0.00% | $2.37B | 63 |
| SGI Somnigroup International Inc | $72.67 | +0.48% | $15.28B | 62 |
| ELF e.l.f. Beauty, Inc. | $60.68 | +4.40% | $3.61B | 59 |
| MIOFF Milbon Co., Ltd. | $52.60 | +0.00% | $1.71B | 58 |
| LIOPF Lion Corporation | $11.51 | +0.00% | $3.18B | 54 |
| IPAR Inter Parfums, Inc. | $102.22 | +2.07% | $3.27B | 54 |
| EWCZ European Wax Center, Inc. | $5.82 | +0.00% | $319.14M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DQWS's Key Strengths?
- Diverse product portfolio in health and beauty.
- Presence in multiple Asian markets.
- Manufacturing capabilities for medical devices and consumables.
- Offers private label manufacturing services.
What Are DQWS's Weaknesses?
- Negative profitability metrics (P/E, profit margin).
- Small market capitalization.
- OTC listing indicates higher risk.
- Limited brand recognition compared to larger competitors.
What Could Drive DQWS Stock Higher?
- Expansion of product line with innovative biotech-nutraceutical solutions to address specific health needs.
- Deepening market penetration in existing Asian markets through strengthened distribution and marketing efforts.
- Leveraging e-commerce platforms to reach a wider customer base and increase brand awareness.
- Offering private label manufacturing services to other companies in the health and beauty industry to generate additional revenue.
- Investing in research and development to create proprietary formulations and differentiate from competitors.
What Are the Key Risks for DQWS?
- Intense competition from established players in the health and beauty industry.
- Fluctuations in currency exchange rates can impact profitability.
- Changes in regulatory requirements in different Asian markets.
- Economic slowdown in key markets can reduce consumer spending.
- Negative profitability metrics (P/E, profit margin) indicate financial challenges.
What Are the Growth Opportunities for DQWS?
- Expanding product line with innovative biotech-nutraceutical solutions: DSwiss can capitalize on the growing consumer interest in health and wellness by introducing new products that address specific health needs. The global nutraceuticals market is projected to reach $441.7 billion by 2026, offering a significant opportunity for DSwiss to increase its market share. Timeline: Ongoing.
- Deepening market penetration in existing Asian markets: DSwiss can focus on strengthening its distribution channels and marketing efforts in Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China. The rising disposable incomes and increasing health awareness in these markets provide a favorable environment for DSwiss to grow its sales. Timeline: Ongoing.
- Leveraging e-commerce platforms to reach a wider customer base: DSwiss can expand its online presence by partnering with e-commerce platforms and developing its own online store. The growth of e-commerce in Asia provides a cost-effective way for DSwiss to reach new customers and increase its brand awareness. The e-commerce market in Southeast Asia is expected to reach $172 billion by 2025. Timeline: Upcoming.
- Offering private label manufacturing services to other companies: DSwiss can leverage its manufacturing capabilities to provide private label services to other companies in the health and beauty industry. This can generate additional revenue streams and diversify the company's business model. The private label market is expected to grow at a CAGR of 5.6% from 2021 to 2026. Timeline: Ongoing.
- Investing in research and development to create proprietary formulations: DSwiss can differentiate itself from competitors by developing unique and effective formulations for its products. This requires investing in research and development and building a team of experienced scientists and researchers. Proprietary formulations can command higher prices and create a competitive advantage. Timeline: Ongoing.
What Opportunities Does DQWS Have?
- Expanding product line with innovative solutions.
- Deepening market penetration in existing markets.
- Leveraging e-commerce platforms for wider reach.
- Increasing demand for health and wellness products in Asia.
What Threats Does DQWS Face?
- Intense competition from established players.
- Fluctuations in currency exchange rates.
- Changes in regulatory requirements.
- Economic slowdown in key markets.
What Are DQWS's Competitive Advantages?
- Proprietary formulations in nutraceutical and skincare products.
- Established distribution network in Asian markets.
- Diverse product portfolio catering to various consumer needs.
- Manufacturing capabilities for medical devices and consumables.
What Does DQWS Do?
DSwiss, Inc., incorporated in 2015 and headquartered in Kuala Lumpur, Malaysia, operates as a biotech-nutraceutical company focused on the development and distribution of health and beauty products. The company's product portfolio includes DSwiss coffee, designed to promote digestive health; DSwiss kiwi, which supports the immune system and enhances skin complexion; DSwiss Triple SC, targeting stem cell benefits; and a variety of skincare products like the DSwiss silk mask, coffee slimming scrub, peppermint slimming gel, new age essence, and enlighten essence cream. Beyond nutraceuticals and skincare, DSwiss also offers medical devices and consumables, including DSwiss BioSpec eyewear, Genmune-Pro for immune system support, SkinEra for various skin conditions, SensiBath gel, SuiSu hand and air sanitizers, and MasterLiv, MasterHeart, and WellG supplements targeting liver, heart, and metabolic health, respectively. The company provides diagnostic equipment such as the DSwiss quantum magnetic analyzer and AI skin analyzer machine. Additionally, DSwiss offers medical consumables like surgical gowns, masks, and protective eyewear, along with DNA microarray genotyping services. DSwiss distributes its products across Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China, catering to a wide range of consumer health and beauty needs. The company also offers turnkey private label manufacturing services, expanding its reach within the industry.
What Products and Services Does DQWS Offer?
- Develops and distributes health and beauty products.
- Offers nutraceutical products like DSwiss coffee and DSwiss kiwi.
- Provides skincare solutions including masks, scrubs, and essences.
- Manufactures medical devices such as BioSpec eyewear and quantum magnetic analyzers.
- Supplies medical consumables like surgical gowns and masks.
- Offers DNA microarray genotyping services.
- Provides private label manufacturing services.
How Does DQWS Make Money?
- Direct sales of health and beauty products through various distribution channels.
- Revenue from medical device and consumable sales.
- Income from DNA microarray genotyping services.
- Fees from private label manufacturing services.
What Industry Does DQWS Operate In?
DSwiss, Inc. operates within the consumer defensive sector, specifically in the household and personal products industry. This sector is generally characterized by stable demand, as consumers continue to purchase essential goods regardless of economic conditions. The market is competitive, with established players like BABB (BAB, Baby Banz North America), CAWW (Cawwaii Global), CLGOF (Clearly Canadian Beverage Corporation), EWLU (Euro Waste Logistics), and GGII (Green Globe International, Inc.) competing for market share. DSwiss differentiates itself through its focus on biotech-nutraceutical products and its presence in Asian markets. The industry is influenced by trends such as increasing consumer awareness of health and wellness, growing demand for natural and organic products, and the rise of e-commerce.
Who Are DQWS's Key Customers?
- Individual consumers seeking health and beauty products.
- Hospitals and clinics purchasing medical devices and consumables.
- Other companies utilizing private label manufacturing services.
DQWS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recientemente, la actividad de los insiders ha mostrado compras significativas, lo que sugiere confianza en el futuro de la empresa.
- El sentimiento de la comunidad en redes sociales ha sido predominantemente positivo, destacando la innovación de DSwiss en su sector.
- Se han observado colaboraciones estratégicas que podrían abrir nuevas oportunidades de mercado para DSwiss.
- El enfoque de la empresa en la sostenibilidad ha resonado bien con los inversores conscientes del medio ambiente.
Bear Case
- A pesar del optimismo, algunos analistas han expresado preocupaciones sobre la competencia creciente en el sector.
- El sentimiento negativo en ciertos foros de inversión indica dudas sobre la capacidad de DSwiss para escalar sus operaciones de manera efectiva.
- Recientes cambios en la gestión han generado incertidumbre sobre la dirección futura de la empresa.
- La falta de resultados financieros sólidos en el último trimestre ha alimentado la cautela entre los inversores.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
DQWS Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
DQWS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DQWS.
Price Targets
Wall Street price target analysis for DQWS.
DQWS MoonshotScore
What does this score mean?
The MoonshotScore rates DQWS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ming Chia Leong
Unknown
Ming Chia Leong leads DSwiss, Inc. with a team of 13 employees. Information regarding Ming Chia Leong's specific background, career history, educational qualifications, and previous roles is not available in the provided data. Therefore, a comprehensive biographical profile cannot be constructed at this time.
Track Record: Due to the limited information available, it is not possible to provide a detailed account of Ming Chia Leong's track record, key achievements, strategic decisions, or company milestones under their leadership. Further data is needed to assess their performance and contributions to DSwiss, Inc.
DQWS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DSwiss, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures, increasing the risk for investors. This tier is also known as the 'Pink Sheets' market, characterized by speculative stocks and a higher potential for fraud or manipulation. Investing in OTC Other stocks requires significant due diligence and a high-risk tolerance due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spread can lead to price volatility.
- Higher potential for fraud or manipulation due to lack of regulatory oversight.
- OTC Other listing indicates the company may not meet minimum financial standards.
- Difficulty in obtaining reliable information for due diligence.
- Verify the company's registration and legal standing.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's debt and cash flow situation.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor before investing.
- Company has been in operation since 2015.
- Offers a diverse range of products and services.
- Presence in multiple Asian markets.
- Provides private label manufacturing services.
What Investors Ask About DSwiss, Inc. (DQWS) — Consumer Defensive
What does DSwiss, Inc. do?
DSwiss, Inc. is a biotech-nutraceutical company that develops, manufactures, and distributes a range of health and beauty products across several Asian markets, including Malaysia, Singapore, and China. Their product line includes nutraceuticals like DSwiss coffee and kiwi, skincare products, medical devices such as BioSpec eyewear, and medical consumables like surgical masks. The company also provides private label manufacturing services, catering to other businesses in the health and beauty sector. DSwiss aims to address consumer needs in digestive health, immunity, and overall well-being through its diverse offerings.
What are the main risks for DQWS?
The main risks for DSwiss, Inc. include intense competition from established players in the health and beauty industry, fluctuations in currency exchange rates, and changes in regulatory requirements in different Asian markets. Additionally, the company faces risks associated with its OTC listing, such as limited financial disclosure, low trading volume, and potential for price volatility. The negative profitability metrics (P/E, profit margin) also indicate financial challenges. Investors should carefully consider these risks before investing in DQWS.
What are the key factors to evaluate for DQWS?
DSwiss, Inc. (DQWS) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does DQWS data refresh on this page?
DQWS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DQWS's recent stock price performance?
DSwiss, Inc. (DQWS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio in health and beauty. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DQWS overvalued or undervalued right now?
Valuing DSwiss, Inc. (DQWS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DQWS?
Before investing in DSwiss, Inc. (DQWS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DQWS to a portfolio?
Key strength of DSwiss, Inc. (DQWS): Diverse product portfolio in health and beauty. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for CEO profile and track record.
- Disclosure status on OTC market is unknown.